Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs

Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs

Aim To identify the incidence and risk factors for hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with resolved HBV receiving biological disease‐modifying antirheumatic drugs (bDMARDs). Method Rheumatoid arthritis patients in whom bDMARD therapy was initiated in our depar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of rheumatic diseases 2019-04, Vol.22 (4), p.574-582
Hauptverfasser: Watanabe, Toshiyuki, Fukae, Jun, Fukaya, Shinji, Sawamukai, Norifumi, Isobe, Masato, Matsuhashi, Megumi, Shimizu, Masato, Akikawa, Kazumasa, Tanimura, Kazuhide, Atsumi, Tatsuya, Koike, Takao
Format: Artikel
Sprache:eng
Schlagworte:
antibodies against HBV surface antigen
biological disease‐modifying antirheumatic drugs
HBV reactivation
resolved HBV
rheumatoid arthritis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim To identify the incidence and risk factors for hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with resolved HBV receiving biological disease‐modifying antirheumatic drugs (bDMARDs). Method Rheumatoid arthritis patients in whom bDMARD therapy was initiated in our departments from April 2009 to July 2016 were reviewed. The patients diagnosed with resolved HBV and whose HBV‐DNA levels had been repeatedly measured were enrolled. The endpoint was HBV reactivation (a positive conversion of HBV‐DNA or unquantifiable cases with positivity
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185X.13401